in the news

Four Key Considerations to Help Prepare for the Next Public Health Threat

As a CDMO, Emergent has been working for more than two decades to develop, manufacture and deliver protections against public health threats and deliver vaccines and therapeutic products for clients. In it's work with biopharma and biotechnology businesses, as well as government and nongovernment organizations, Emergent provides the technology, expertise and talent to help quickly and efficiently ramp up manufacturing and development for its clients' products.

During COVID-19, Emergent deployed new processes, and technologies to manufacture novel coronavirus vaccine and therapeutic candidates for CDMO clients. That experience has doubled as a learning opportunity for the future. In this article, Emergent team members reflect on lessons learned through COVID-19 and share four consideration to help prepare for the next public health threat.

Read Article


Lyophilized products are on the rise: Here's what you need to know

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug...


Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...

EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...